Telescoping Tubridge Flow Diverter Treatment in Giant Middle Cerebral Artery Fusiform Aneurysm

  • Hetai Lai Zhuhai Hospital Affiliated With Jinan University (Zhuhai People's Hospital)
DOI: https://doi.org/10.18686/aem.v12i2.357
Keywords: Flow Diverter, Endovascular Treatment, Middle Cerebral Artery, Fusiform Aneurysm, Tubridige

Abstract

Giant fusiform aneurysm of the middle cerebral artery is a rare lesion with a high risk of rupture and high mortality, which is more difficult to treat either surgically or endovascularly. We report a case of a giant middle cerebral artery (MCA) M1 segmental fusiform aneurysm treated with the Tubridge Flow Diverter (TFD) telescoping technique alone without coil embolization. The patient had a single TFD implanted initially after the accidental discovery of a giant left MCA fusiform aneurysm, and after 3 months of postoperative shortening of the proximal end of the TFD and no significant healing of the aneurysm, a second TFD was implanted in the second stage by Telescoping technique. the aneurysm healed completely at 6 and 18 months after procedure, with no significant complications during follow-up. 

References

[1] Xu F, Xu B, Huang L, et al. Surgical Treatment of Large or Giant Fusiform Middle Cerebral Artery Aneurysms: A Case Series [J]. World Neurosurg, 2018, 115(e252-e62.

[2] Ikeda DS, Marlin ES, Shaw A, et al. Successful endovascular reconstruction of a recurrent giant middle cerebral artery aneurysm with multiple telescoping flow diverters in a pediatric patient [J]. Pediatr Neurosurg, 2015, 50(2): 88-93.

[3] Griffin A, Lerner E, Zuchowski A, et al. Flow diversion of fusiform intracranial aneurysms [J]. Neurosurg Rev, 2021, 44(3): 1471-8.

[4] Monteith SJ, Tsimpas A, Dumont AS, et al. Endovascular treatment of fusiform cerebral aneurysms with the Pipeline Embolization Device [J]. J Neurosurg, 2014, 120(4): 945-54.

[5] Xu C, Wu P, Zou L, et al. Anterior Circulation Fusiform Aneurysms Have a Lower Occlusion Rate After Pipeline Embolization Device Treatment Than Posterior Circulation Fusiform Aneurysms: A Multicenter Cohort Study [J]. Front Neurol, 2022, 13(925115.

[6] Tang H, Shang C, Hua W, et al. The 8-year single-center experience of telescoping flow diverter for complex intracranial aneurysms treatment [J]. J Clin Neurosci, 2022, 100(131-7.

[7] Fischer S, Perez M A, Kurre W, et al. Pipeline embolization device for the treatment of intra- and extracranial fusiform and dissecting aneurysms: initial experience and long-term follow-up [J]. Neurosurgery, 2014, 75(4): 364-74; discussion 74.

[8] Chalouhi N, Tjoumakaris S, Phillips JL, et al. A single pipeline embolization device is sufficient for treatment of intracranial aneurysms [J]. AJNR Am J Neuroradiol, 2014, 35(8): 1562-6.

[9] Damiano RJ, Ma D, Xiang J, et al. Finite element modeling of endovascular coiling and flow diversion enables hemodynamic prediction of complex treatment strategies for intracranial aneurysm [J]. J Biomech, 2015, 48(12): 3332-40.

[10] Uchiyama Y, Fujimura S, Takao H, et al. Hemodynamic Investigation of the Effectiveness of a Two Overlapping Flow Diverter Configuration for Cerebral Aneurysm Treatment [J]. Bioengineering (Basel), 2021, 8(10).

[11] Miyachi S, Hiramatsu R, Ohnishi H, et al. Usefulness of the Pipeline Embolic Device for Large and Giant Carotid Cavernous Aneurysms [J]. Neurointervention, 2017, 12(2): 83-90.

[12] Xie D, Zhao L, Liu H, et al. Tubridge Flow Diverter for the Treatment of Unruptured Dissecting Cerebral Aneurysms [J]. World Neurosurg, 2023.

[13] Liu JM, Zhou Y, Li Y, et al. Parent Artery Reconstruction for Large or Giant Cerebral Aneurysms Using the Tubridge Flow Diverter: A Multicenter, Randomized, Controlled Clinical Trial (PARAT) [J]. AJNR Am J Neuroradiol, 2018, 39(5): 807-16.

[14] Aquarius R, De Korte A, Smits D, et al. The Importance of Wall Apposition in Flow Diverters [J]. Neurosurgery, 2019, 84(3): 804-10.
Published
2023-06-01
Issue
Vol 12, No 2 (2023)
Section
Original Research Article

Copyright (c) 2023 Hetai Lai

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.